BRAF and Lynch syndrome: Since biomarker testing was mostly relevant for patients considered for anti-EGFR therapy (KRAS, NRAS) or younger patients (MMR testing for Lynch syndrome or BRAF testing for prognostication), it is possible that more young and fit patients with mCRC were tested.